BioSpace News Archive

Since the emergence of SARS-CoV-2, public health laboratories and researchers have been developing surveillance methods using wastewater to control the spread of COVID-19.

The Boston Athletic Association (B.A.A.) and Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that Quest will be the exclusive provider of onsite COVID-19 testing for the 125th Boston marathon, to be held Monday, October 11.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new research paper was published demonstrating Thymosin Beta 4’s (Tβ4) positive effects on animal models related to Alzheimer’s Disease.

Scopus BioPharma Inc. (Nasdaq: “SCPS”), today announced it will be presenting at the LD Micro Main Event, which is being held in-person and virtually from October 12th through 14th, 2021.

EmphyCorp Inc. www.EmphyCorp.com, a private corporation, specializes in Rx Non-Steroidal Nasal Spray Technology.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces its management will present at the Lytham Partners Fall 2021 Investor Conference.

RhoVac AB, a Swedish cancer immunotherapy company, announces on October 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 2018.

Exo Therapeutics, Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, announced the completion of a $78 million Series B financing.

T-Cure Bioscience, Inc. and Atlas Antibodies AB , a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, announced today a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb.

AlzeCure Pharma AB announced that the company’s presentation and poster regarding the research platform in neurology, NeuroRestore, its connection to BDNF/TrkB signaling and potential therapeutic role in depression, as presented at the European College of Neuropsychopharmacology 2021 on 2-5 October in Lisbon, Portugal, are now available in its entirety on the company’s website.